Unravel Biosciences

We're moving so fast it's scary. Happy Halloween! To catch up, check out our latest newsletter: https://lnkd.in/ekq4Tdtw 🎉 New lab and office opening 💊 Signed clinical trial agreement for our first two trials 🙏 Many new partnerships initiated - all to rapidly advance patient treatments

Being scared is fun during Halloween but not in healthcare. We at Unravel Biosciences are working hard in partnership with patients, families, and clinicians to realize a world where no patient lacks effective treatment, no matter how rare or complex the disorder. #paradigmchange

We are thrilled to announce a major clinical trial milestone in #Rettsyndrome #therapeutics development! Unravel Biosciences signed a #clinicaltrial agreement with PECET at the Universidad de Antioquia in Medellin, Colombia. We are rapidly progressing to test our lead asset, RVL-001, in parallel trials in #Rett and #PittHopkins syndromes. This represents a major step towards accelerating drug development for all complex disorders, and we are excited to work with the clinical team to efficently translate disease-modifying therapeutics into the clinic https://lnkd.in/ebdxu_Js.

What if clinicians could discover new ways to effectively treat even the most complex disorders... within a couple months? Unravel's AI drug target discovery platform has enabled just that! Dive into this heartwarming story shared by Elizabeth, a mother whose son, Max is battling KMT2B dystonia. Discover how Max’s participation in the rareSHIFT rapid drug repurposing program at Unravel Biosciences has opened new doors to recovery, rapidly restoring multiple biological functions and hope for Max and his family. We are proud to partner with families like Max and Elizabeth and witness the powerful impact of our innovative approach in tackling complex diseases. https://lnkd.in/giBTg2V3 #rare #disease #drug #development

We are thrilled to announce the opening of Unravel Biosciences' new, expanded HQ in Medford, MA, marking a major milestone in our mission to develop effective therapeutics for patients, no matter how complex or rare their disease. This new facility will greatly enhance and grow our research and development capabilities, enabling us to accelerate the discovery of therapeutics for more patients in need. It takes a village to build a startup, and we are grateful to the incredible support we received from the New England biotech and university communities and our dedicated partners. Thanks to Wyss Institute at Harvard University Director and Co-Founder Donald Ingber, M.D., Ph.D., Representative Paul Donato, Medford Mayor Breanna Lungo-Koehn, MassBio President Kendalle Burlin O'Connell, The Jackson Laboratory VP Madeleine Braun, Ph.D., MBA, and Zymo Research Corp VP Keith Booher for attending. Additionally, the many families and foundation leaders who graciously joined our celebration and the heartwarming story of June's positive response thanks to Unravel's personalized data analysis was a meaningful reminder of why we put #patientsfirst. We’re looking forward to pushing the boundaries of science and making a meaningful difference for the rare disease community. Thank you to everyone who honored and supported us by attending our opening celebration! https://lnkd.in/gc-aGkJE #RareDisease #Therapeutics #Startup #DrugDevelopment

Excited to be pitching Unravel Biosciences at #RESI during #BostonBiotechWeek

Congratulations to Richard Novak, Frederic Vigneault, and the rest of the Unravel Biosciences team on moving to a new headquarters! This is the space where treatments to rare diseases will be found and the lives of patients will be improved.

It’s a good opportunity to learn more about how we Unravel the biological network of complex disorders, discover new targets rooted in patients data and validate the mechanism in patients.

We are closing the drug discovery and clinical impact loop! Thrilled to collaborate with The Jackson Laboratory to change the paradigm of drug development, starting with #rarediseases. By combining the strengths of both organizations, patients will benefit from a streamlined preclinical development path to potential treatments and clinical trials driven by primary patient data to optimize safety and efficacy. The renowned mouse model and preclinical study expertise at JAX complements Unravel's AI-enabled drug and target discovery platform powered by primary patient RNA data. Even in the couple weeks since signing the agreement, we have already advanced novel discoveries for the first indication, demonstrating just how revolutionary this collaboration may be to patients in need. https://lnkd.in/edgFrnT3

Unravel's CEO, Richard Novak, will be presenting at #RESIBOSTON on September 25th and participating in partnering and investor meetings throughout the event. Sign up for meetings in the link below!